Latest News and Press Releases

RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...

~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients...

RESEARCH TRIANGLE PARK, N.C., May 28, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New...

~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~ ~ Company Has Approximately $27...

~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~ ~ Resubmission of the NDA for PEDMARKTM is Planned...

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~ ~ No Clinical Safety or Efficacy Issues...

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...

RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that Rosty Raykov, Chief Executive Officer of Fennec...

~ No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data ~ ~ FDA Pre-Approval Inspection has Identified Deficiencies with the Facility of the Drug Product...

~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~~ Strong Financial Position with $38.7 million in cash and no debt ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE...